Drug Trial Radar · NCT05732805
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Aug 2, 2022
Primary completion
Jun 20, 2024
Study completion Jul 2025
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.
Conditions
- Melanoma
- Melanoma (Skin)
- Melanoma Stage III
- Melanoma Stage IV
- Melanoma Unresectable
- Melanoma Metastatic
- Melanoma Advanced
Interventions
BCD-217Biological
Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
BCD-100Biological
Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: 24 months
Locations
63 sites in 3 countries. Site status is shown where the registry gives one.
Healthcare Institution "Bobruisk Interdistrict Oncological Dispensary"
Babruysk, Belarus
Healthcare Institution "Brest Regional Oncological Dispensary"
Brest, Belarus
Health care institution "Grodno University Clinic"
Grodno, Belarus
Health Institution "Gomel Regional Clinical Oncology Center"
Homyel, Belarus
State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov"
Lesnoy, Belarus
Healthcare Institution "Minsk City Clinical Cancer Center"
Minsk, Belarus
State Institution "Mogilev Regional Oncological Dispensary"
Mogilev, Belarus
Healthcare Institution "Vitebsk Regional Clinical Oncology Center"
Vitebsk, Belarus
Fortis Hospital
Faridabad, India
Kasturba Medical College and Hospital
Mangalore, India
TATA Memorial Hospital
Mumbai, India
HealthCare Global Enterprises Ltd, NCHRI Cancer Center
Nagpur, India
HealthCare Global Enterprises Ltd Manavata cancer Centre
Nashik, India
Sankalp Superspeciality Hospital
Nashik, India
All India Institute of Medical Science
New Delhi, India
Deenanath Mangeshkar Hospital & Research Center
Pune, India
PDEAS Ayurved Rugnalaya & Steriling Multispeciality Hospital
Pune, India
Horizon Mulitispeciality Hospital
Sangli, India
Shalby Hospital
Surat, India
Kiran Multispeciality hospital &Research
Sūrat, India
Arkhangelsk Clinical Oncology Dispensary
Arkhangelsk, Russia
Regional State Budgetary Institution of Health Care "Altai Regional Oncological Dispensary"
Barnaul, Russia
Limited Liability Company "EVIMED"
Chelyabinsk, Russia
Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Chelyabinsk"
Chelyabinsk, Russia
State budgetary healthcare institution Leningrad Regional Clinical Hospital
Gatchina, Russia
State Autonomous Health Institution "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"
Kazan', Russia
State budgetary health care institution "Kuzbass clinical oncological dispensary named after M.S. Rappoport"
Kemerovo, Russia
Regional Goverment Budgetary Healthcare State "Kostroma Oncology Center"
Kostroma, Russia
State Budgetary Institution of Healthcare "Leningrad Regional Clinical Oncological Dispensary named after V.I. L.D. Romana"
Kuz'molovskiy, Russia
"Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation
Moscow, Russia
Branch of Hadassah Medical LTD Limited Liability Company
Moscow, Russia
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Moscow, Russia
Joint Stock Company "K31 City"
Moscow, Russia
JSC "Medsi Group"
Moscow, Russia
Moscow City Oncology Hospital No. 62
Moscow, Russia
State budgetary health care institution of the city of Moscow "City Clinical Oncology Hospital No. 1 of the Department of Health of the City of Moscow"
Moscow, Russia
State Budgetary Institution of Healthcare of the City of Moscow "Moscow Multidisciplinary Clinical Center "Kommunarka" of the Department of Health of the City of Moscow"
Moscow, Russia
Nizhny Novgorod Region State Budgetary Healthcare Facility "Clinical Diagnostics Center"
Nizhny Novgorod, Russia
LLC "DobroMed"
Novosibirsk, Russia
State Budgetary Healthcare Institution "Novosibirsk Regional Clinical Oncology Center" of the Novosibirsk Region
Novosibirsk, Russia
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.